Cipla has reported results for fourth quarter and year ended March 31, 2021.
The company has reported a fall of 31.62% in its net profit at Rs 413.41 crore for the quarter under review as compared to Rs 604.57 crore for the same quarter in the previous year. Total income of the company decreased by 7.45% at Rs 3,282.45 crore for Q4FY21 as compared Rs 3,546.85 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 68.07% in its net profit attributed to shareholders at Rs 413.38 crore for the quarter under review as compared to Rs 245.95 crore for the same quarter in the previous year. Total income of the company increased by 4.41% at Rs 4,666.58 crore for Q4FY21 as compared Rs 4,469.37 crore for the corresponding quarter previous year.
For the year ended March 31, 2021, the company has reported a rise of 6.48% in its net profit at Rs 2,468.28 crore as compared to Rs 2,318.17 crore for the previous year. Total income of the company increased by 4.27% at Rs 14,130.86 crore for year under review as compared to Rs 13,552 crore for year ended March 31, 2020.
For the year ended March 31, 2021, on the consolidated basis, the company has reported a rise of 55.50% in its net profit at Rs 2,404.87 crore as compared to Rs 1,546.52 crore for the previous year. Total income of the company increased by 11.15% at Rs 19,425.58 crore for year under review as compared to Rs 17,476.19 crore for year ended March 31, 2020.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1523.80 |
Dr. Reddys Lab | 5959.10 |
Cipla | 1352.95 |
Zydus Lifesciences | 934.50 |
Lupin | 1599.65 |
View more.. |